Claudia Palena, Potomac, MD (US); Zhimin Guo, Superior, CO (US); David Apelian, Boonton Township, NJ (US); and Jeffrey Schlom, Potomac, MD (US)
Assigned to The USA, as represented by the Secretary, Dept. of Health and Human Services, Bethesda, MD (US); and GlobeImmune, Inc., Louisville, CO (US)
Filed by GlobeImmune, Inc., Louisville, CO (US); and The USA, as represented by the Secretary, Dept. of Health and Human Services, Bethesda, MD (US)
Filed on Dec. 21, 2020, as Appl. No. 17/129,633.
Application 17/129,633 is a continuation of application No. 16/389,235, filed on Apr. 19, 2019.
Application 16/389,235 is a continuation of application No. 15/454,176, filed on Mar. 9, 2017, granted, now 10,363,294, issued on Jul. 30, 2019.
Application 15/454,176 is a continuation of application No. 14/926,372, filed on Oct. 29, 2015, granted, now 9,623,097, issued on Apr. 18, 2017.
Application 14/926,372 is a continuation of application No. 13/803,719, filed on Mar. 14, 2013, granted, now 9,198,941, issued on Dec. 1, 2015.
Application 13/803,719 is a continuation of application No. PCT/US2012/029636, filed on Mar. 19, 2012.
Claims priority of provisional application 61/453,656, filed on Mar. 17, 2011.
Prior Publication US 2021/0106666 A1, Apr. 15, 2021
b) a cancer antigen comprising a Brachyury antigen, wherein the Brachyury antigen comprises an amino acid sequence of positions 2-435 of SEQ ID NO:6; and
c) a pharmaceutically acceptable excipient suitable for administration to a human.